Intellia Therapeutics
Trade Intellia Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About NTLA
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.
NTLA Key Statistics
Stock Snapshot
The current Intellia Therapeutics(NTLA) stock price is $12.97, with a market capitalization of 1.51B. The stock trades at a price-to-earnings (P/E) ratio of -3.06.
As of 2026-02-04, Intellia Therapeutics(NTLA) stock has fluctuated between $12.51 and $13.75. The current price stands at $12.97, placing the stock +3.7% above today's low and -5.7% off the high.
The Intellia Therapeutics(NTLA)'s current trading volume is 3.62M, compared to an average daily volume of 7.24M.
In the last year, Intellia Therapeutics(NTLA) shares hit a 52-week high of $28.25 and a 52-week low of $5.90.
In the last year, Intellia Therapeutics(NTLA) shares hit a 52-week high of $28.25 and a 52-week low of $5.90.
NTLA News
Intellia Therapeutics (NTLA) attracted investor attention after the FDA removed the clinical hold on its MAGNITUDE-2 Phase 3 trial. This decision allows enrollm...
Intellia Therapeutics Inc (NTLA) announced an update on their ongoing clinical study. Study Overview – Intellia Therapeutics is running a Phase 1 study called...
In late January 2026, Intellia Therapeutics announced that the FDA removed the clinical hold on its MAGNITUDE-2 Phase 3 trial of CRISPR-based therapy nexiguran...
Analyst ratings
46%
of 26 ratingsMore NTLA News
If you are wondering whether Intellia Therapeutics at around US$14.83 is a bargain or a value trap, you are not alone. The stock has returned 15.6% over the la...
Baird raised the firm’s price target on Intellia Therapeutics (NTLA) to $7 from $4 and keeps a Neutral rating on the shares. The firm updated its model followin...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.